• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EPOS2020/EUFOREA 专家意见:慢性鼻窦炎伴鼻息肉患者疾病分型和治疗目标的定义。

EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP.

机构信息

Department of Otorhinolarynogology and head/neck surgery, Amsterdam University Medical Centres, location AMC, University of Amsterdam, Amsterdam, The Netherlands.

Otolaryngology, Head and Neck Surgery, Rhinology, A. Gemelli Universitary Hospital Foundation, IRCSS, Rome, Italy.

出版信息

Rhinology. 2024 Jun 1;62(3):287-298. doi: 10.4193/Rhin23.415.

DOI:10.4193/Rhin23.415
PMID:38217529
Abstract

Severe chronic rhinosinusitis with nasal polyps (CRSwNP), a form of diffuse bilateral (usually type 2) CRS, is a debilitating disease with a significant impact on quality of life (QoL). With novel knowledge and treatment options becoming available, there is a growing need to update or revise key definitions to enable communication across different specialties dealing with CRS, and to agree on novel goals of care in CRSwNP. The European Forum for Research and Education in Allergy and Airway diseases (EUFOREA) and EPOS expert members discussed how to measure treatment responses and set new treatment goals for CRSwNP. In this paper a consensus on a list of definitions related to CRSwNP is provided: control, remission, cure, recurrence/exacerbation, treatable traits, remodeling, progression, and disease modification. By providing these definitions, the involved experts hope to improve communication between all stakeholders involved in CRSwNP treatment for use in routine care, basic and clinical research and international guidelines aimed to harmonize and optimize standard of care of patients with CRSwNP in the future.

摘要

伴有鼻息肉的慢性鼻-鼻窦炎(CRSwNP)是一种弥漫性双侧疾病(通常为 2 型),是一种使人虚弱的疾病,对生活质量(QoL)有重大影响。随着新的知识和治疗方案的出现,人们越来越需要更新或修改关键定义,以促进处理 CRS 的不同专业之间的交流,并就 CRSwNP 的新治疗目标达成一致。欧洲过敏和气道疾病研究与教育论坛(EUFOREA)和 EPOS 专家成员讨论了如何衡量 CRSwNP 的治疗反应并设定新的治疗目标。本文就与 CRSwNP 相关的一系列定义达成了共识:控制、缓解、治愈、复发/加重、可治疗特征、重塑、进展和疾病修饰。通过提供这些定义,相关专家希望改善所有涉及 CRSwNP 治疗的利益相关者之间的沟通,以便在常规护理、基础和临床研究以及旨在协调和优化未来 CRSwNP 患者护理标准的国际指南中使用。

相似文献

1
EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP.EPOS2020/EUFOREA 专家意见:慢性鼻窦炎伴鼻息肉患者疾病分型和治疗目标的定义。
Rhinology. 2024 Jun 1;62(3):287-298. doi: 10.4193/Rhin23.415.
2
EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care.EUFOREA/EPOS2020 关于慢性鼻-鼻窦炎伴鼻息肉患者护理的临床考量声明。
Allergy. 2024 May;79(5):1123-1133. doi: 10.1111/all.15982. Epub 2023 Dec 18.
3
EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management.欧盟鼻科学专家组会议关于未控制的严重慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)和生物制剂:定义和管理。
J Allergy Clin Immunol. 2021 Jan;147(1):29-36. doi: 10.1016/j.jaci.2020.11.013. Epub 2020 Nov 20.
4
EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023.2023 年 EPOS/EUFOREA 关于生物制剂治疗慢性鼻-鼻窦炎伴鼻息肉的适应证和评估的更新。
Rhinology. 2023 Jun 1;61(3):194-202. doi: 10.4193/Rhin22.489.
5
The EUFOREA pocket guide for chronic rhinosinusitis.欧盟慢性鼻窦炎袖珍指南。
Rhinology. 2023 Feb 1;61(1):85-89. doi: 10.4193/Rhin22.344.
6
Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps.嗜酸性粒细胞是目前严重难治性伴鼻息肉慢性鼻窦炎生物治疗指征中的主要2型标志物。
Rhinology. 2024 Jun 1;62(3):383-384. doi: 10.4193/Rhin23.081.
7
[Chronic Rhinosinusitis - EPOS 2012 Part I].[慢性鼻-鼻窦炎——2012年EPOS第一部分]
Laryngorhinootologie. 2013 Mar;92(3):193-201; quiz 202-3. doi: 10.1055/s-0033-1333704. Epub 2013 Feb 21.
8
Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis.度普利尤单抗治疗伴有鼻息肉的慢性鼻-鼻窦炎。
Expert Opin Biol Ther. 2021 May;21(5):575-585. doi: 10.1080/14712598.2021.1901881. Epub 2021 Apr 1.
9
[Chronic rhinosinusitisand type 2 disease].[慢性鼻-鼻窦炎与2型疾病]
Ugeskr Laeger. 2022 Mar 7;184(10).
10
European Position Paper on Rhinosinusitis and Nasal Polyps 2020.欧洲鼻窦炎和鼻息肉 2020 年立场文件。
Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.

引用本文的文献

1
Evaluation of extended dupilumab dosing intervals Q2W (biweekly) versus Q4W (monthly) in chronic rhinosinusitis with nasal polyposis: a real-world study from Saudi Arabia : Extended dupilumab dosing in CRSwNP.评估度普利尤单抗延长给药间隔(每2周一次[双周一次]对比每4周一次[每月一次])用于伴鼻息肉的慢性鼻-鼻窦炎:沙特阿拉伯的一项真实世界研究:伴鼻息肉的慢性鼻-鼻窦炎中延长度普利尤单抗给药方案。
Eur Arch Otorhinolaryngol. 2025 Sep 18. doi: 10.1007/s00405-025-09677-2.
2
Combined corticosteroid therapy enhances outcomes of endoscopic sinus surgery in chronic rhinosinusitis with nasal polyps: a prospective cohort study.联合皮质类固醇治疗可改善慢性鼻-鼻窦炎伴鼻息肉患者的鼻内镜手术疗效:一项前瞻性队列研究
Am J Transl Res. 2025 Jul 15;17(7):5173-5185. doi: 10.62347/XYEC4626. eCollection 2025.
3
Remission in chronic rhinosinusitis with nasal polyps treated with biologics: a real-life experience.生物制剂治疗鼻息肉型慢性鼻-鼻窦炎的缓解情况:真实病例经验
Eur Arch Otorhinolaryngol. 2025 Sep;282(9):4681-4690. doi: 10.1007/s00405-025-09619-y. Epub 2025 Aug 4.
4
Strategies for Tapering the Dosage of Biologics Targeting Type 2 Inflammation: A Systematic Review.降低靶向2型炎症生物制剂剂量的策略:一项系统评价
Curr Allergy Asthma Rep. 2025 Jul 28;25(1):32. doi: 10.1007/s11882-025-01214-9.
5
The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis.2型慢性鼻-鼻窦炎伴鼻息肉病理生理机制的研究进展
Front Allergy. 2025 Jul 2;6:1599797. doi: 10.3389/falgy.2025.1599797. eCollection 2025.
6
ULANC - EUFOREA workshop 2024: bringing the concept of global airways to the frontline of medical care.ULANC - 2024年欧盟呼吸病学研讨会:将全球气道概念引入医疗一线
Front Allergy. 2025 Jun 30;6:1581694. doi: 10.3389/falgy.2025.1581694. eCollection 2025.
7
The Diagnostic Accuracy of the Nasopharyngeal Reflux Endoscopic Score (NRES) for Identifying Laryngopharyngeal Reflux Disease in Chronic Rhinosinusitis.用于识别慢性鼻-鼻窦炎中喉咽反流疾病的鼻咽反流内镜评分(NRES)的诊断准确性
J Clin Med. 2025 Jun 17;14(12):4293. doi: 10.3390/jcm14124293.
8
PM2.5 Induced Nasal Mucosal Barrier Dysfunction and Epithelial-Mesenchymal Transition to Promote Chronic Rhinosinusitis Through IL4I1-AhR Signaling Pathway.PM2.5通过IL4I1-AhR信号通路诱导鼻黏膜屏障功能障碍和上皮-间质转化,从而促进慢性鼻-鼻窦炎
Toxics. 2025 Jun 10;13(6):488. doi: 10.3390/toxics13060488.
9
Dupilumab-Induced Remission in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: A 24-Month Study.度普利尤单抗诱导伴鼻息肉和合并哮喘的慢性鼻-鼻窦炎缓解:一项24个月的研究
J Clin Med. 2025 May 23;14(11):3654. doi: 10.3390/jcm14113654.
10
Quality of life in type 2 and non-type 2 endotypes in chronic rhinosinusitis with nasal polyps: A prospective trial.伴有鼻息肉的慢性鼻窦炎中2型和非2型内型的生活质量:一项前瞻性试验。
Clin Transl Allergy. 2025 Jun;15(6):e70070. doi: 10.1002/clt2.70070.